Baltimore-Washington Financial Advisors’s AbbVie ABBV Stock Holding History

Baltimore-Washington Financial Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$463K	Buy	1,839 +19	+1%	+$4.09K	0.02%	138
2026 Q1	$396K	Sell	1,820 -32	-2%	-$7.1K	0.02%	134
2025 Q4	$423K	Buy	1,852 +62	+3%	+$14.1K	0.02%	130
2025 Q3	$414K	Buy	1,790 +60	+3%	+$12.2K	0.02%	125
2025 Q2	$321K	Buy	1,730 +233	+16%	+$43.3K	0.02%	136
2025 Q1	$314K	Buy	+1,497	New	+$291K	0.02%	125
2024 Q4	–	Sell	-1,029	Closed	-$203K	–	154
2024 Q3	$203K	Buy	+1,029	New	+$192K	0.01%	146
2024 Q1	–	Sell	-1,429	Closed	-$221K	–	127
2023 Q4	$221K	Buy	+1,429	New	+$208K	0.02%	137
2023 Q2	–	Sell	-1,484	Closed	-$237K	–	139
2023 Q1	$237K	Buy	+1,484	New	+$227K	0.02%	131
2014 Q1	–	Sell	-200	Closed	-$11K	–	222
2013 Q4	$11K	Buy	+200	New	+$9.83K	﹤0.01%	227

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Baltimore-Washington Financial Advisors's ABBV Position: Q2 2026 in Review

Baltimore-Washington Financial Advisors increased its AbbVie (ABBV) stake by 1% in Q2 2026, buying an estimated $4.09K and bringing the position to 1,839 shares worth $463K. The position accounts for 0.02% of the portfolio, ranked #138.

Baltimore-Washington Financial Advisors first reported a position in ABBV in Q4 2013 and has held it in 10 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Baltimore-Washington Financial Advisors held 1,839 shares of AbbVie worth $463K as of Q2 2026.
Baltimore-Washington Financial Advisors bought 19 AbbVie shares in Q2 2026, an estimated $4.09K.
AbbVie made up 0.02% of Baltimore-Washington Financial Advisors's portfolio in Q2 2026, its #138 holding.
Baltimore-Washington Financial Advisors first reported a position in AbbVie in Q4 2013 and has held it in 10 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Baltimore-Washington Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.